PHILADELPHIA -- The majority of women with cancer causing BRCA1 and BRCA2 mutations experience sexual dysfunction, menopausal symptoms, cognitive and stress issues, and poor sleep following prophylactic removal of their Fallopian tubes and ovaries - a procedure known as risk-reducing salpingo-oophorectomy (RRSO) - according to results of a new study from the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania. The team's findings, which reaffirm the need for a better understanding of how to manage long-term effects of the risk-reducing procedure, will be presented during the annual meeting of the American Society of Clinical Oncology in Chicago's McCormick Place on Saturday, May 31, 2014 (abstract #1508).
"These results reinforce the need for care providers to better understand and communicate with patients about the possible long-term effects of bilateral RRSO," said lead author Susan Domchek, MD, director of Penn's Basser Research Center for BRCA. "Removal of the Fallopian tubes and ovaries is associated with a decreased risk of death from breast and ovarian cancer for BRCA carriers, and is one of the most important interventions we have at the current time. However, this procedure comes with a price, so it's extremely important that clinicians work with women to help alleviate symptoms."
The new study surveyed 637 women with BRCA1 or BRCA2 mutations who had undergone the risk-reducing surgical procedure to have both ovaries and Fallopian tubes removed. Domchek and colleagues assessed participant quality-of-life through a series of questionnaires. Results show that suboptimal scores were present in the majority of patients for the majority of measures. Specifically, 73 percent reported sexual dysfunction, such as the absence of satisfaction and presence of pain; 61 percent had problems sleeping; 57 percent had symptoms of menopause such as hot flashes and vaginal dryness; and 56 percent had elevated levels of stress. Hormone replacement therapy did help mitigate symptoms, particularly in women undergoing oophorectomy prior to age 50.
Currently, it is recommended that BRCA1/2 mutation carriers undergo oophorectomy between ages 35-40 given the substantial benefits in decreasing breast and ovarian cancer risk and improving overall survival. "Our work highlights the need for novel strategies to prevent breast and ovarian cancer. Despite the efficacy of oophorectomy, given the negative impact, we need to continue to strive towards other options for prevention".
Other Penn authors on the study include Laura DiGiovanni, Chan Voong, Rebecca Mueller, Lauren Johnson, C. Neill Epperson, MD, and Clarisa Gracia, MD. This study was supported by the Komen Foundation for the Cure and the Basser Research Center for BRCA.
Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $4.3 billion enterprise.
The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 17 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $392 million awarded in the 2013 fiscal year.
The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; Chester County Hospital; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Chestnut Hill Hospital and Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2013, Penn Medicine provided $814 million to benefit our community.